Compare Adaptive Biotechnologies Corp (ADPT) vs Amcor PLC (AMCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Amcor PLC — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Amcor PLC trades at $41.94 (market cap $20.55B). The key difference: Amcor PLC is far larger — about 6.2× Adaptive Biotechnologies Corp's market cap, and Amcor PLC pays a 5.85% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AMCR | |
|---|---|---|
Market Cap | $3.33B | $20.55B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $50.58 |
52-Week Low | $10.24 | $36.69 |
Enterprise Value | $3.19B | $35.67B |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AMCR trades at $44.45, down 1.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $15.01B in 2025, with net income of $511M, and has beaten EPS estimates for the last three quarters. Recent news highlights sustainable packaging partnerships and leadership changes aimed at growth.
The stock offers a moderate upside to the consensus price target of $45.75, supported by a 69% analyst buy rating, but faces risks from integration challenges post-Berry acquisition and a high P/E ratio of 35.84. Earnings growth and synergy realization are key catalysts for 2027 recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →
